This result was consistent with a previous report that median PFS of NSCLC patients with BRAF mutations received platinum‐based combination chemotherapy was similar to patients with BRAF wild type (5.2 vs. 6.7 months, P = 0.622) 28. Here, BRAF is linked to non-small cell lung carcinoma.